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Abstract
Background
Although depressive symptoms in first episode psychosis have been associated with can-
nabis abuse, their influence on the long-term functional course of FEP patients who abuse
cannabis is unknown. The aims of the study were to examine the influence of subclinical de-
pressive symptoms on the long-term outcome in first episode-psychosis patients who were
cannabis users and to assess the influence of these subclinical depressive symptoms on
the ability to quit cannabis use.
Methods
64 FEP patients who were cannabis users at baseline were followed-up for 5 years. Two
groups were defined: (a) patients with subclinical depressive symptoms at least once during
follow-up (DPG), and (b) patients without subclinical depressive symptoms during follow-up
(NDPG). Psychotic symptoms were measured using the Positive and Negative Syndrome
Scale (PANSS), depressive symptoms using the Hamilton Depression Rating Scale
(HDRS)-17, and psychosocial functioning was assessed using the Global Assessment of
Functioning (GAF). A linear mixed-effects model was used to analyze the combined influ-
ence of cannabis use and subclinical depressive symptomatology on the clinical outcome.
Results
Subclinical depressive symptoms were associated with continued abuse of cannabis during
follow-up (β= 4.45; 95% confidence interval [CI]: 1.78 to 11.17; P = .001) and with worse
functioning (β = -5.50; 95% CI: -9.02 to -0.33; P = .009).
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Conclusions
Subclinical depressive symptoms and continued cannabis abuse during follow-up could be
predictors of negative outcomes in FEP patients.
Introduction
Substance use disorders are commonly associated with other comorbid psychiatric disorders
[1], [2]. Specifically, cannabis use has been associated with mental health problems [3], [4], [5],
increased risk of psychosis [5], [6], [7], [8] and earlier onset of psychosis [9],[10],[11]. Once
psychosis has begun, continued cannabis use has been associated with poorer functional out-
comes [12],[13],[14]. Recent intervention studies aimed at reducing cannabis use and improv-
ing the prognosis of patients with recent-onset psychosis have been unsuccessful with low rates
of effectiveness [15], [16]. Consequently, researchers have focused on identifying factors that
mediate continued use of cannabis and some studies indicate that depressive symptoms may
be a relevant factor [17],[18],[19].
Depressive symptoms of all levels of severity are common in patients with first-episode psy-
chosis (FEP) [20], [21], [22], [23], [24], irrespective of whether they are cannabis abusers or
not [16], [19]. Studies examining depressive symptoms in FEP patients (with and without can-
nabis abuse) have found that those with depressive symptoms have poorer outcomes with
more suicidal thinking, more negative symptoms and worse functionality during follow-up
[23], [24]. In a recent systematic review, anxiety and depression in FEP patients were related to
the severity of psychotic symptoms and to worse clinical outcomes [19].
The evidence for an association between cannabis abuse and the type or number of depres-
sive symptoms is conflicting. According to the self-medication hypothesis, subclinical depres-
sive symptoms can cause social difficulties and psychological distress that may be relieved by
cannabis abuse, [25]. Some studies have found an association between cannabis abuse and the
presence of fewer or less severe depressive symptoms [26], [27], suggesting that cannabis use
may alleviate some of these symptoms. Other studies, however, have observed an increase in
negative [28] or depressive [17], [29] symptoms when Δ9-tetrahydrocannabinol (THC), the
main psychoactive constituent of cannabis, is administered to patients with schizophrenia.
Therefore, it remains unclear whether cannabis abuse relieves or induces depression-related
symptoms. In a previous longitudinal study, FEP patients who stopped using cannabis had im-
proved functioning and a significant reduction in negative symptoms in the long-term, whereas
continued cannabis use was associated with poorer long-term outcomes [14]. From a neurobi-
ological perspective, it is well known that THC acts on the cannabinoid system in the brain,
which plays a role in emotional regulation [30]. However, the relationship between cannabis
use and depressive symptoms is complex. Recent findings suggest the effect of cannabis use on
depressive symptoms might be moderated by genetic factors, specifically the short allele of the
serotonin transporter gene-linked polymorphic region (5-HTTLPR) genotype; i.e., cannabis
use increases the risk for a worsening of depressive symptoms in individuals with this genetic
vulnerability [30].
Thus, there is a strong evidence for the negative impact of prolonged cannabis use on long-
term clinical and functional outcomes in FEP patients [13], [14], [31]. However, little is known
about the influence of depressive symptoms on the long-term functioning of FEP patients with
cannabis abuse, or the effect of depressive symptoms on the ability of patients to stop cannabis
consumption [17], [18], [19]. Specifically, subclinical depression (i.e., a level of depressive
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symptoms that are below the threshold for a diagnosis of clinical depression), which is more
common in these patients during follow-up, has not been studied.
The aims of this study were to examine the influence of subclinical depressive symptoms on
long-term functional and clinical outcomes, and on the ability of patients to stop using canna-
bis. We hypothesized that patients with FEP who use cannabis and have persistent subclinical
depressive symptoms during follow-up would have poorer functional and clinical outcomes, as
well as a worse course for their addictive disorder, compared with patients without depressive
symptoms during follow-up.
Material and Methods
Subjects
The study was conducted on patients who were cannabis users admitted for the first time with
a first psychotic episode to Alava University Hospital of Alava-Santiago between 2003 and
2007. A first psychotic episode was defined according to the revised fourth edition of the Diag-
nostic and Statistical Manual of Mental Disorders (DSM-IV-TR) [32]. Cannabis use/abuse/
dependence was defined according to DSM-IV-TR criteria and the scores of the European ad-
aptation of the fifth version of the Addiction Severity Index (Europ-ASI) [33] (Table 1), and
from information obtained from urine drug analyses. The FEP patients included in the study
were aged 16–45 years and met the DSM-IV-TR diagnostic criteria for one of the following dis-
orders: schizophreniform disorder; schizoaffective disorder; schizophrenia; delusional disorder;
brief psychotic disorder; atypical psychosis; bipolar I/II disorder. Patients with major depres-
sion, substance-induced psychotic disorders, mental retardation or organic brain disorders
were excluded from the study.
Procedure
Patients were assessed clinically by trained psychologists or psychiatrists at baseline and at 1, 3,
and 5 years of follow-up. The baseline assessment was conducted during the hospitalization for
the first episode psychotic. Urine drug screens were performed at the follow-up assessments
and a positive result confirmed that cannabis or other substances were being used. The study
was approved by the Ethics Committee (Institutional Research Board) of University Hospital
of Alava-Santiago. All participating patients were enrolled after providing written informed
consent. In case of patients not capacitated to consent or minor patients, a legally authorized
representative consented on the behalf of participants.
Table 1. Severity of Cannabis Use.
Severity of
consumption
DSM-IV-TRa criteria for abuse or dependence Europ-ASIb
scores
Dependence Meet minimal or more DSM-IV criteria for cannabis dependence 8–9
Abuse Meet 1 criteria for cannabis abuse 4–7
Use Abuse criteria but do not meet temporal criteria (at least 12 mo) or
use 12 mo but not fulﬁlling any criteria of DSM-IV abuse
2–3
No use No signiﬁcant symptoms 0–1
aFourth edition of the Diagnostic and Statistical Manual of Mental Disorders, revised edition (DSM-IV-TR).23
bEuropean Addiction Severity Index (Europ-ASI).25
doi:10.1371/journal.pone.0123707.t001
Subclinical Depressive Symptoms and Cannabis Use
PLOS ONE | DOI:10.1371/journal.pone.0123707 April 15, 2015 3 / 12
Assessments
The DSM-IV-TR axis I diagnosis was made using the Structured Clinical Interview for
DSM-IV-TR (SCID-I) [34]. Psychotic symptoms were measured using the Positive and Nega-
tive Syndrome Scale (PANSS) [35], [36], depressive symptoms were measured using the Ham-
ilton Depression Rating Scale (HDRS-17) [37], [38], and psychosocial functioning was
assessed using the Global Assessment of Functioning (GAF) [39], [40]. The clinical interview
was carried out independently by two experienced clinicians to ensure the reliability of diag-
noses. The data on inter-rater reliability obtained were satisfactory for SCID-I diagnoses
(κ = 0.86) and for the scales used: PANSS (κ = 0.78); HDRS-17 (κ = 0.79); GAF (κ = 0.93) and
Europ-ASI (κ = 0.90).
Severity of cannabis use was determined according to the DSM-IV-TR criteria for abuse or
dependence and the 9-point scale of the Europ-ASI [33], [41] and patients were categorized as:
no use, use, abuse and dependence as shown in Table 1.
For determining the influence of subclinical depressive symptoms on clinical outcomes and
their potential relationship to quitting cannabis use during follow-up, patients were classified
into 2 groups according to the presence of subclinical depressive symptoms during follow-up:
(1) patients with subclinical depressive symptoms at least once during follow-up (DPG); and
(2) patients without subclinical depressive symptoms during follow-up (NDPG). Subclinical
depressive symptoms (i.e., depressive symptoms below the threshold for a diagnosis of clinical
depression) were defined as present when the HDRS-17 score was greater than or equal to
8 (score range is 0–54), [42], [43].
Data Analysis
Analyses were carried out using the Statistical Package for the Social Sciences (SPSS) version
21.0 for Windows and R 2.5.1 [44]. Descriptive summary statistics (means, standard devia-
tions [SD], frequencies, percentages) were used to describe the sociodemographic and baseline
clinical characteristics of the total patient sample and by the presence/absence of subclinical
depressive symptoms during follow-up. Differences at baseline between the two depressive
symptom groups (DPG and NDPG) were performed using the χ2 test or Fisher test for cate-
gorical variables, and the Student t-test or Mann-Whitney U test for continuous variables, de-
pending on whether normality and size assumptions held. The variables with significant
differences between groups were used as covariates in the subsequent analyses, after checking
the collinearity.
A linear mixed-effects model was used to analyze the combined influence of cannabis use
and subclinical depressive symptomatology on the clinical outcome of patients. The dependent
variable was the GAF score. Cannabis use and depressive symptoms (HDRS-17 score8) were
included as fixed-effects and patient was included as a random effect in the model. Assessments
at 1, 3 and 5 years after the first episode of psychosis were accounted for in the analysis. The
maximum likelihood test was used to assess goodness of fit. Analysis of variance (ANOVA)
was used to assess inclusion in the final model of the depression and cannabis use interaction
term. Results are expressed as β coefficients with 95% confidence intervals (CI) and P values.
Logistic regression models were used to analyze the association between the subclinical de-
pressive symptoms during follow-up (present or absent) and clinical outcomes at 5 years. Data
are presented as odds ratios (OR) with 95% CIs and P values. Differences between groups
(DPG and NDPG) in the severity of the other substance consumption (alcohol, tobacco, etc)
were analyzed using Fisher exact tests.
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Results
Baseline Characteristics of the Sample
At baseline, 74 patients met the inclusion criteria and were enrolled in the study. However, 6
patients dropped out of the study during follow-up and a further 4 patients were excluded
from the analysis because they had a diagnosis of major depression during follow-up. Thus, the
total sample analyzed was 64 FEP patients with cannabis use who were followed-up for 5 years.
At baseline, 17 (26.6%) patients had bipolar disorder, 16 (25%) had schizophrenia, and 31
(48.4%) had other psychotic disorders (13 patients had brief psychotic disorder and 18 patients
had psychotic disorder not otherwise specified). The sociodemographic and baseline clinical
characteristics of the 10 patients excluded from the analysis did not differ from those of the pa-
tients included the analysis.
Of the 64 patients in the total sample, 36 (56.3%) were in the DPG group and 28 (43.8%)
were in the NDPG. Table 2 summarizes the sociodemographic and baseline clinical character-
istics of the total sample and of the two groups by presence/absence of subclinical depressive
symptoms during follow-up (DPG, NDPG). These two groups did not differ, except for socio-
economic status and level of education (Fisher, P<. 05); DPG patients had a lower socioeco-
nomic status and lower level of education. The mean HDRS-17 score did not differ between
the DPG and NDPG groups. The severity of cannabis use did not differ significantly between
groups (Fisher, P = .054). In the DPG group, 8.3% of patients met the criteria for cannabis use
and 91.7% for cannabis abuse. In the NDPG group, 10.7% of patients met the criteria for can-
nabis use, 75% for abuse, and 14.3% for dependence. There were not significant differences be-
tween groups in alcohol, tobacco and other substances (cocaine, amphetamine, and heroine).
Follow-up Results
Association between Severity of Cannabis Use, Depressive Symptoms and Function-
ing. The results of the fixed-effects model showed that the presence of subclinical depressive
symptoms during follow-up (HDRS-17 score 8) was associated with continued cannabis
abuse (4–7 points on the Europ-ASI scale) during follow-up (β = 4.45; 95% CI: 1.78 to 11.17;
P = .001) and with worse functioning during follow-up (β = -5.50; 95% CI: -9.02 to -0.33;
P = .009) (1, 3 and 5 years). In addition, cannabis abuse during follow-up was associated with a
lower score on the GAF scale (i.e. poorer functioning), compared with no use of cannabis
during follow-up (β = -4.71; 95% CI: -9.04 to -0.31; P = .038), whereas cannabis use during fol-
low-up (2–3 points on the Europ-ASI scale) was not significantly associated with functioning
(β = -2.03; 95% CI: -11.40 to 7.34; P = .669). The effects of depressive symptoms and cannabis
use were independent because the interaction term for these two variables showed no signifi-
cant influence on the GAF score (P = .863).
Other Outcomes at Follow-up. The clinical status of patients at each of the follow-up
evaluations is provided in Table 3. Logistic regression analyses of the association between de-
pressive symptoms and clinical symptomatology at 5-years follow-up showed that the presence
of subclinical depressive symptoms during follow-up (DPG) was associated with more PANSS
positive symptoms (OR = 1.20; 95% CI: 1.07 to 1.36; P = .004), PANSS negative symptoms
(OR = 1.13; 95% CI: 1.05 to1.23; P = .003), and PANSS general symptoms (OR = 1.21; 95% CI:
1.10 to 1.33; P<. 001) at year 5 than the absence of subclinical depressive symptoms during
follow-up (NDPG). DPG was also associated with poorer psychosocial functioning (OR = 0.92;
95% CI: 0.88 to 0.96; P<. 001) compared with NDPG. In addition, the clinical course was
worse for patients in the DPG group; they had more than twice the probability of having hospi-
talizations (OR = 2.07; 95% CI: 1.29 to 3.30; P = .002) and episodes of psychosis (OR = 2.55;
Subclinical Depressive Symptoms and Cannabis Use
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95% CI: 1.51 to 4.31; P<. 001) by year 5 of follow-up, compared with the NDPG group. The
mean number of hospitalizations during the 5-year follow-up was 4.41 (SD 3.29) and 1.89 (SD
1.23) in the DPG and NDPG groups, respectively. Likewise, the mean number of psychotic epi-
sodes was 5.03 (SD 2.93) vs 2.29 (SD1.21) in the DPG and NDPG groups, respectively. The
mean (SD) number of suicide attempts did not differ between the DPG (0.38 ± 0.78) and
NDPG groups (0.14 ± 0.36; P = .157).
During the 5-years of follow-up, cannabis use was reduced in both the DPG and NDPG
groups. There was no significant difference in the severity of cannabis use between the two
groups at year 5 (Fisher, P = .056): 50% of the DPG group vs. 71.4% of the NDPG group did
not use cannabis, 8.3% vs. 10.7% used cannabis, 41.7% vs. 14.3% abused cannabis, and 0% vs.
Table 2. Sociodemographic and Baseline Clinical Characteristics of the Total Sample and by Subclinical Depressive Symptomatology During Fol-
low-up.
Total (n = 64) DPGa (n = 36) NDPGb (n = 28) P Value
Sex Male 37 (57.8%) 17 (47.2%) 20 (71.4%) χ2 = 3.78 (P = .052)
Female 27 (42.2%) 19 (52.8%) 8 (28.6%)
Age 24.75 ± 5.99 24.58 ± 4.93 24.96 ± 7.21 U = 485.5 (P = .802)
Civil status Single 57 (89.1%) 31 (86.1%) 26 (92.9%) Fisher (P = .840)
Married 4 (6.3%) 3 (8.3%) 1 (3.6%)
Other 3 (4.7%) 2 (5.6%) 1 (3.6%)
Socioeconomic status Low 17 (26.6%) 14 (38.9%) 3 (10.7%) Fisher (P = .004)
Medium 41 (64.1%) 19 (52.8%) 22 (78.6%)
High 6 (9.4%) 3 (8.3%) 3 (10.7%)
Education level No education 3 (4.8%) 2 (5.6%) 1 (3.7%) Fisher (P = .044)
Primary school 21 (33.3%) 12 (33.3%) 9 (33.3%)
Secondary school 34 (54%) 22 (61.1%) 12 (44.4%)
College 5 (7.9%) 0 (0%) 5 (18.5%)
Occupation Active 28 (43.8%) 17 (47.2%) 11 (39.3%) Fisher (P = .125)
Unemployed 19 (29.7%) 13 (36.1%) 6 (21.4%)
Other 17 (26.5%) 6 (16.7%) 11 (39.3%)
Cannabis use Use 6 (9.4%) 3 (8.3%) 3 (10.7%) Fisher (P = .054)
Abuse 54 (84.4%) 33 (91.7%) 21 (75%)
Dependence 4 (6.3%) 0 (0%) 4 (14.3%)
Other substances Tobacco 54 (84.4%) 29 (80.6%) 25 (89.3%) χ2 = 0.64 (P = .425)
Alcohol 42 (65.6%) 26 (72.2%) 16 (57.1%) χ2 = 1.59 (P = .208)
Other 34 (53.1%) 17 (47.2%) 17 (60.7%) χ2 = 1.15 (P = .283)
Antipsychotics Atypical 44 (68.8%) 29 (80.6%) 15 (53.6%) χ2 = 3.36 (P = .067)
Typical 20 (31.3%) 12 (33.3%) 8 (28.6%) χ2 = 0.15 (P = .698)
PANSS Positive 25.47 ± 6.44 25.19 ± 7.34 25.82 ± 5.16 U = 491 (P = .860)
Negative 17.48 ± 8.76 18.08 ± 8.77 16.71 ± 8.84 U = 452 (P = .481)
General 41.56 ± 10.38 41.67 ± 8.97 41.43 ± 12.21 U = 451 (P = .473)
GAF 50.48 ± 15.22 49.78 ± 12.11 51.39 ± 18.67 U = 489 (P = .839)
HDRS-17 18.55 ± 7.20 17.44 ± 8.17 19.96 ± 5.54 U = 417.5 (P = .241)
Notes: Data are presented as mean ± SD or n (%). The percentage given for each variable refers to the total n available for that variable. P values are
results of Chi-square (categorical variables) and Mann-Whitney U tests (continuous variables). Values in bold are signiﬁcant at P<.05. PANSS, Positive
and Negative Syndrome Scale; GAF, Global Assessment of Functioning; HDRS-17, Hamilton Depression Rating Scale.
aDPG = patients with subclinical depressive symptoms at least once during the 5 year follow-up.
bNDPG = patients without subclinical depressive symptoms during the 5 year follow-up.
doi:10.1371/journal.pone.0123707.t002
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3.6% had cannabis dependence. Severity of alcohol use differed significantly between the DPG
and NDPG groups at year 5 of follow-up (Fisher, P = .001): in the DPG group, 15.2% of pa-
tients did not use alcohol, 42.4% met the criteria for alcohol use, and 42.4% for alcohol abuse;
while in the NDPG group, 12% of patients had no alcohol consumption, 80% were using alco-
hol, but only 4% were abusing or dependent on alcohol. Finally, the use of other substances
did not differ between groups at year 5: 27.3% in the DPG group vs. 8% in the NDPG group;
Fisher, P = .108.
Discussion
This study has three main findings. First, FEP patients with cannabis abuse who have subclini-
cal depressive symptoms during 5 years of follow-up have a poorer clinical and functional out-
come, compared with patients without subclinical depressive symptoms during follow-up.
Second, subclinical depressive symptoms during long-term follow-up are associated with con-
tinued cannabis abuse. Third, continued cannabis abuse is associated with poorer
functional outcome.
Although other studies have examined long-term outcomes in FEP patients with regards to
depressive symptoms [17], [18], [19], [23], [24], this is the first study to analyze the role of sub-
clinical depressive symptoms in a sample of FEP patients who were cannabis users. Depressive
symptoms often appear at the onset of early psychosis and subsequently decrease, remaining at
a lower level during the course of the disease [20], [21], [22], [23], [24]. This persistence or
presence of subclinical depressive symptoms is not universal, at least in patients with cannabis
abuse. In our sample, we identified two groups of patients (those with and without subclinical
depressive symptoms during follow-up) who clearly differed in their long-term outcomes. Pa-
tients with subclinical depressive symptoms during 5 years’ follow-up had poorer long-term
Table 3. Clinical status of patients at follow-up.
Total (n = 64) DPGa (n = 36) NDPGb (n = 28)
PANSS Positive 1 year 12.90±7.22 16.00±7.97 9.04±3.45
3 years 13.25±6.59 16.24±6.88 9.71±4.05
5 years 13.03±7.13 16.15±7.95 9.48±3.74
PANSS Negative 1 year 12.19±6.55 14.06±7.26 9.86±4.66
3 years 14.28±8.14 17.42±8.94 10.57±5.12
5 years 15.73±8.42 19.27±9.05 11.69±5.41
PANSS General 1 year 26.54±9.61 31.54±9.78 20.29±4.31
3 years 29.69±11.12 33.61±11.39 22.53±6.01
5 years 29.79±10.77 35.45±10.91 23.34±5.97
HDRS-17 1 year 8.87±7.13 12.00±7.44 4.96±4.32
3 years 8.21±7.07 11.73±7.58 4.07±3.17
5 years 8.32±5.88 11.82±5.23 4.34±3.64
GAF 1 year 61.94±14.63 57.60±14.37 67.36±13.26
3 years 61.38±14.48 55.48±12.28 68.32±13.94
5 years 63.00±16.14 55.21±14.93 71.86±12.65
Notes: Data are presented as mean ± SD. PANSS, Positive and Negative Syndrome Scale; GAF, Global Assessment of Functioning; HDRS-17, Hamilton
Depression Rating Scale.
aDPG = patients with subclinical depressive symptoms at least once during the 5 year follow-up.
bNDPG = patients without subclinical depressive symptoms during the 5 year follow-up.
doi:10.1371/journal.pone.0123707.t003
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outcomes, with more negative psychotic symptoms and poorer psychosocial functioning.
These results are consistent with the study by Sönmez et al. [23] which showed that FEP pa-
tients with persistent depression had poorer functioning and more negative symptoms at 12
months follow-up. Birchwood et al. [45] have suggested that persistent depression is an essen-
tial aspect of schizophrenia that is associated with disease severity and negative symptoms. Our
results show that the link between depression and negative symptoms is particularly important
in patients with comorbid cannabis use, although the etiology of the association remains un-
clear [19]. There are at least three hypotheses that could explain the relationship between sub-
clinical depressive symptoms and cannabis abuse: (1) depressive symptoms are a consequence
of cannabis abuse [46]; (2) the self-medication theory [25], [47], [48], [49]; and (3) a common
genetic or environmental vulnerability for both disorders [46]. It is possible that all three may
play a role, although our results can only be discussed with regards to the first two hypotheses.
Lynskey et al. [46] showed that patients with depressive episodes in adolescence were more
likely to have subsequent cannabis dependence, and that cannabis dependence was associated
with a higher risk of subsequent major depression in dizygotic, but not in monozygotic twins.
Our results indicate that subclinical depressive symptoms are enough to make it difficult for
FEP patients to stop using cannabis.
For the second hypothesis (self-medication), symptoms of apathy or lack of motivation fa-
cilitate the appearance of a depressed mood, which, in turn, is associated with an increased risk
of cannabis consumption in an attempt by patients to relieve their negative emotional state
[25]. Often these patients show a poor repertoire of behaviors, with a lack of rewarding activi-
ties in their daily life, except for the addictive substance [47]. This raises the question of wheth-
er cannabis use could be the consequence of subclinical depressive symptoms. Our results
suggest that patients who have greater vulnerability to maintain subclinical depressive symp-
toms during follow-up are more likely to continue cannabis use in the long term, while patients
without subclinical depressive symptoms are more able to discontinue cannabis consumption.
One factor that may contribute to the difficulty in stopping cannabis use among patients with
subclinical depression is the anxiolytic effects of its two main constituents, THC and cannabi-
diol [50], [51].
The third finding of this study is that FEP cannabis users who stopped using cannabis dur-
ing follow-up had better functional outcomes. It is important to understand why some patients
stopped using cannabis while others continued to use it. One possible explanation for failing to
stop cannabis use, according to our results, is the presence of subclinical depressive symptoms
during follow-up. Interestingly, there was no significant interaction between the independent
variables cannabis use and depressive symptoms on functional outcome. This means that both
cannabis abuse (β = -4.7), and depressive symptoms (β = -5.5) have a negative and independent
effect on the functional outcome (GAF score), and when both are present the effect is additive
rather than multiplicative. Because cannabis use and depressive symptoms have an indepen-
dent effect on functioning, there must be a complex underlying mechanism.
Another finding of this study is that patients with subclinical depressive symptoms during
follow-up not only had more positive psychotic symptoms in the long-term, but also more al-
cohol abuse. In a recent systematic review, Hartley et al. [19] found that the presence of anxiety
and depressive symptoms is associated with severity of psychosis and with positive symptoms.
Thus, depressive symptoms could be a potential target in the treatment of psychosis [19]. In a
previous study, we observed that FEP patients who continued using cannabis during 8 years of
follow-up exhibited poorer long-term functioning and had more negative symptoms than pa-
tients who stopped using cannabis [14].
This study has several limitations that must be taken into account when interpreting the
findings. These limitations include the small sample size and the naturalistic setting of the
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study. The absence of a neuropsychological assessment is another limitation of the study, given
that cognitive impairment has been reported to be a mediator of cannabis use and its relation-
ship with depressive symptoms in some populations [52]. However, assessment of cognition
was not a primary objective of the study. A further limitation is the low number of evaluations
during the follow-up period, which does not allow us to determine any firm association be-
tween depression and poor functioning. The lack of premorbid assessments means that we can-
not rule out that poor functioning was present before the start of cannabis abuse. In addition,
at baseline the HDRS score is higher (although not significantly) in the NPDG group compared
to the DPG group. These subtle differences at baseline would be difficult to observe under the
conditions of severity of psychotic symptoms at admission for a psychotic episode. Finally, the
role of sex should be considered in future studies, since depression is more common in females,
but cannabis use is more prevalent in males.
The strengths of our study include the long follow-up for 5 years and the representativeness
of the sample, which includes the majority of FEP patients who were cannabis users in psychi-
atric care in the geographic area of Vitoria.
Conclusions
In conclusion, our findings suggest that subclinical depressive symptoms and continued canna-
bis abuse during long-term follow-up could be predictors of negative outcomes in FEP patients.
Patients with a low level of depression are less likely to quit using cannabis and are at risk of
experiencing more severe psychosis during follow-up. Subclinical depressive symptoms should
be a therapeutic target in FEP patients to prevent the development of an unfavorable clinical
and functional course, especially in cannabis users.
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